ARS Pharmaceuticals, Inc. SPRY Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $24.32M-39.0% | $41.32M-18.7% | $59.56M+50.2% | $51.54M+40.7% | $39.86M-28.8% | ||
| $176.65M-25.1% | $203.67M-22.6% | $228.65M+38.6% | $188.59M+3.6% | $235.86M+40.7% | ||
| $28.66M+208% | $25.35M+210% | $36.45M+4,616% | $25.13M— | $9.3M— | ||
| $23.22M+94.5% | $23.05M+334% | $13.65M+1,808% | $13.37M— | $11.94M— | ||
| $6.79M-41.3% | $6.19M-10.0% | $6.42M+140% | $7.44M+273% | $11.56M+343% | ||
| $245.24M-19.3% | $284.9M-14.8% | $338.86M+62.3% | $281.44M+27.5% | $303.86M+34.3% | ||
| $2.29M+113% | $2.47M+131% | $1.21M+43.4% | $1.08M+69.0% | $1.08M+74.5% | ||
| $14.18M+95.8% | $14.45M+96.1% | $14.73M+96.4% | $12.97M— | $7.24M— | ||
| $2.65M-15.3% | $2.79M-10.5% | $2.92M+674% | $3.05M+584% | $3.13M+493% | ||
| $287.57M-12.1% | $327.65M-6.7% | $372.8M+71.3% | $313.47M+41.2% | $327.32M+43.8% | ||
| $48.26M+78.7% | $37.95M+66.1% | $49.77M+201% | $44.26M+574% | $27.01M+672% | ||
| $592K— | $588K+1,300% | —— | —— | —— | ||
| $757K+40.2% | $609K+9.3% | $526K— | $746K— | $540K— | ||
| $978K-27.0% | $1.13M-26.2% | $1.27M— | $1.1M— | $1.34M— | ||
| $49.61M+79.6% | $39.15M+67.0% | $50.88M+206% | $45.6M+578% | $27.62M+644% | ||
| $96.52M— | $96.37M— | $96.23M— | —— | —— | ||
| $226.26M+130% | $213.39M+126% | $225.15M+1,254% | $121.15M+1,702% | $98.34M+2,547% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $10K0.0% | $10K0.0% | $10K0.0% | $10K0.0% | $10K0.0% | ||
| $416.62M+7.9% | $408.73M+7.6% | $400.93M+7.2% | $394.49M+6.8% | $386.14M+5.6% | ||
| -$355.22M-126% | -$294.6M-139% | -$253.28M-46.2% | -$202.13M-31.2% | -$157.25M-11.1% | ||
| -$96K-233% | $125K-43.2% | -$7K-102% | -$46K+68.3% | $72K+158% | ||
| $61.31M-73.2% | $114.26M-55.5% | $147.66M-26.5% | $192.32M-10.6% | $228.97M+2.3% | ||
| $287.57M-12.1% | $327.65M-6.7% | $372.8M+71.3% | $313.47M+41.2% | $327.32M+43.8% | ||
| $8.82M— | $8.37M+60.6% | $7.78M— | $8.74M— | —— | ||
| $14.18M+95.8% | $14.45M+96.1% | $14.73M+96.4% | $12.97M— | $7.24M— | ||
| $2.65M-15.3% | $2.79M-10.5% | $2.92M+674% | $3.05M+584% | $3.13M+493% | ||
| $176.65M-25.1% | $203.67M-22.6% | $228.65M+38.6% | $188.59M+3.6% | $235.86M+40.7% | ||
| $978K-27.0% | $1.13M-26.2% | $1.27M— | $1.1M— | $1.34M— | ||
| $48.26M+78.7% | $37.95M+66.1% | $49.77M+201% | $44.26M+574% | $27.01M+672% | ||
| $592K— | $588K+1,300% | —— | —— | —— | ||
| $978K-27.0% | $1.13M-26.2% | $1.27M— | $1.1M— | $1.34M— | ||
| $978K-27.0% | $1.13M-26.2% | $1.27M— | $1.1M— | $1.34M— | ||
| $96.52M+132,122% | $96.37M+229,362% | $97.76M+95,744% | $1.66M+938% | $73K-66.4% | ||
| $10K0.0% | $10K0.0% | $10K0.0% | $10K0.0% | $10K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $74.67M+7.6% | $72.14M+4.0% | $72.04M— | $71.96M— | $69.38M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ARS Pharmaceuticals, Inc.'s total assets?
- ARS Pharmaceuticals, Inc. (SPRY) holds $287.6M in total assets, down 12.1% year over year.
- How much debt does ARS Pharmaceuticals, Inc. have?
- ARS Pharmaceuticals, Inc. carries $96.5M in total debt against $61.3M of shareholders' equity, a debt-to-equity ratio of 1.57.
- How much cash does ARS Pharmaceuticals, Inc. have?
- ARS Pharmaceuticals, Inc. holds $24.3M in cash and equivalents.
- Can ARS Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 4.94 — current assets exceed current liabilities.
- Where does ARS Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
